Citations

Institution: Mayo Clinic Clear

Showing 10 of 108081 citations.

Activity of Spectinomycin Against Anaerobes
Rosenblatt, Jon E., Gerdts, A.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 12 | Issue: 1 | Pages: 37-39

10.1128/aac.12.1.37 | PMID 18985 Get It

The in vitro inhibitory activity of spectinomycin was tested against various anaerobic bacteria. Different results were obtained with different media and with different initial pH's of the media. The highest minimum inhibitory concentrations for Bacteroides fragilis ([Formula: see text] 128 μg/ml) were obtained with the use of Wilkins-Chalgren agar (pH 7.2) and Brucella blood agar (pH 7.0). Brucella blood agar at higher pH's (7.4 and 8.0) and Mueller-Hinton and Diagnostic Sensitivity Test agars produced lower minimum inhibitory concentrations (32 and 64 μg/ml). This same relationship between spectinomycin activity and pH of the medium was, in general, observed with these media and other anaerobes, including isolates of B. melaninogenicus, Fusobacterium , gram-positive cocci, Clostridium perfringens , and C. ramosum . The variable results observed in this study and in two others make it difficult to predict the clinical usefulness of spectinomycin in the treatment of anaerobic infections. It is probably most appropriate to be guided by results obtained with Wilkins-Chalgren agar and the method proposed as a reference to the National Committee for Clinical Laboratory Standards. These results indicate that spectinomycin is not a potent inhibitor of B. fragilis or other clinically significant anaerobes.
Gas Chromatographic Determination of 5-Fluorocytosine: a Modified Extraction Method
Wee, Siok-Hui, Anhalt, John P.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 11 | Issue: 5 | Pages: 914-915

10.1128/aac.11.5.914 | PMID 879744 Get It

A modified procedure for the gas-chromatographic determination of 5-fluorocytosine in serum is described. A more volatile solvent mixture for extraction is used to reduce sample preparation time before chromatography. Comparison of values from assay of 12 serum samples by our method and the reference method gave a correlation coefficient of 0.99.
Assay of Gentamicin in Serum by High-Pressure Liquid Chromatography
Anhalt, John P.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 11 | Issue: 4 | Pages: 651-655

10.1128/aac.11.4.651 | PMID 856016 Get It

A procedure is described that uses high-pressure liquid chromatography for assay of gentamicin in serum. The technique involves extraction of gentamicin from serum by using a CM-Sephadex column and analysis by reverse-phase, ion-pair chromatography. Continuous-flow, post-column derivatization with o -phthaladehyde is used to form fluorescent products for detection. The possible scope of this method for analysis of other aminoglycoside antibiotics is illustrated by application to sisomicin and netilmicin.
Penicillin Resistance and Penicillinase Production in Clinical Isolates of Bacteroides melaninogenicus
Murray, Patrick R. , Rosenblatt, Jon E.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 11 | Issue: 4 | Pages: 605-608

10.1128/aac.11.4.605 | PMID 16564 Get It

The minimum inhibitory concentrations (MIC) of penicillin and six other antimicrobials were determined for 50 clinical isolates of Bacteroides melaninogenicus . Agar dilution susceptibilities were performed using supplemented brucella blood agar and the proposed National Committee for Clinical Laboratory Standards standard method for anaerobes; results with the two methods were comparable. A penicillin concentration ≥0.8 μg/ml was needed to inhibit 56% of the isolates, whereas 100% were susceptible to 0.1 μg of clindamycin per ml. All isolates with penicillin MIC values ≥0.8 μg/ml produced β-lactamase using a slide method. A micro-iodometric assay was used to quantitate β-lactamase production in six isolates. The β-lactamase activity of B. melaninogenicus was comparable to that of a Staphylococcus aureus isolate but was not inducible, and the specific amount produced correlated only partially with penicillin MIC values. A clinical review of patients from whom the β-lactamase-producing strains of B. melaninogenicus were isolated did not suggest any increased virulence in these strains or an unexpectedly poor clinical response to appropriate therapy.
Comparison of In Vitro Activity of Cephalexin, Cephradine, and Cefaclor
Bill, Nancy J., Washington, John A.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 11 | Issue: 3 | Pages: 470-474

10.1128/aac.11.3.470 | PMID 301005 Get It

Inhibitory activity of cephalexin, cephradine, and cefaclor was compared by the WHO-ICS agar dilution technique. Cefaclor was substantially more active against staphylococci, streptococci, gonococci, meningococci, Haemophilus, Escherichia coli, Klebsiella pneumoniae, Citrobacter diversus, Proteus mirabilis , salmonellae, and shigellae than was cephalexin, which in turn was more active than cephradine. Cefaclor appeared to be less resistant to staphylococcal penicillinase than did the other two agents. None of these cephalosporins was active against Enterobacter, Serratia , indole-positive Proteeae, Pseudomonas , or Bacteroides fragilis .
Comparison of Direct and Standardized Antimicrobial Susceptibility Testing of Positive Blood Cultures
Johnson, James E. , Washington, John A.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 10 | Issue: 2 | Pages: 211-214

10.1128/aac.10.2.211 | PMID 984763 Get It

In an effort to determine the feasibility and accuracy of performing direct susceptibility tests from positive blood cultures, minimal inhibitory concentrations (MICs), determined by the agar dilution method, of direct and standardized tests with seven antibiotics were compared. Results were analyzed as to the number of very major (change in MIC from susceptible in preliminary direct testing to resistant in final standardized testing), major (change in MIC from resistant to susceptible), and minor (change in MIC without change in interpretation) discrepancies. The results for gram-positive cocci and for gram-negative bacilli were 5, 6, and 82 of 162 strains tested and 3, 12, and 79 of 90 strains tested, respectively. Of the total number of susceptibility tests compared, major and very major discrepancies occurred in only 1 and 2.4% of instances with gram-positive and -negative isolates, respectively. The majority of discrepancies were noted with Staphylococcus epidermidis (four very major, five major), Klebsiella (two very major, four major), and Alcaligenes (five major). The antibiotics most often exhibiting discrepancies were penicillin, ampicillin, and cephalothin. The results indicate that preliminary susceptibility testing directly from positive blood culture bottles is generally both feasible and accurate.
In Vitro Antimicrobial Susceptibility of Anaerobic Bacteria Isolated from Clinical Specimens
Martin, William J., Gardner, Mildred, Washington, John A., Martin, William J.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 1 | Issue: 2 | Pages: 148-158

10.1128/aac.1.2.148 | PMID 4680804 Get It

The minimal inhibitory concentrations of 601 clinical isolates of anaerobic bacteria to 10 different antimicrobial agents were determined by an agar-dilution technique. Nearly all strains were resistant to kanamycin and gentamicin, although moderate activity to both drugs was noted with Fusobacterium sp., anaerobic cocci, some strains of Bacteroides melaninogenicus , and nonsporeforming gram-positive bacilli. Chloramphenicol at 12.5 μg/ml inhibited all but three of the strains tested. Tetracycline at 6.25 μg/ml had high activity against all groups tested, with the exception that only 39% of strains of Bacteroides fragilis were inhibited at this concentration. Excluding certain species of Bacteroides , the majority of anaerobes were inhibited by penicillin at 3.1 μg/ml or less and by cephalothin at 12.5 μg/ml or less. Lincomycin at 6.2 μg/ml or less was active against nearly all strains. Erythromycin at a concentration of 3.1 μg/ml was active against B. fragilis ; however, erythromycin was less active against the other groups. Most of the minimal inhibitory concentrations of lincomycin exceeded those of clindamycin by fourfold. Rifampin inhibited virtually all strains at 3.1 μg/ml.
Four-Hour Microbiological Assay of Gentamicin in Serum
Warren, Edward, Snyder, Robert , Washington, John A.

Antimicrobial Agents and Chemotherapy | June 27, 2012 | Volume: 1 | Issue: 1 | Pages: 46-48

10.1128/aac.1.1.46 | PMID 4670428 Get It

Since the microbiological assay of the antibiotic content of serum generally requires 18 to 24 hr of incubation, results of such procedures may not become available in time to make appropriate adjustments in subsequent dosages of antibiotic. A 4-hr bioassay for determining concentrations of gentamicin in serum has been developed in which Staphylococcus aureus ATCC 6538P is used as the test organism. Poured plates have yielded satisfactory results after storage at 4 C for 5 days. Results of the 4-hr procedure agree closely with those of a conventional 18-hr disc-plate assay performed with the same test organism.
Abstract 5485: mTOR inhibition promotes autophagy that reduces chemosensitivity and is partially restored by chloroquine
Huang, Shengbing, Yu, Chunrong, Sinicrope, Frank A.

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 5485-5485

10.1158/1538-7445.am2011-5485 Get It

Abstract BACKGROUND. The mammalian target of rapamycin (mTOR) kinase forms two multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, cell survival, and autophagy. We determined whether mTOR inhibition can induce cytoprotective autophagy resulting in anti-cancer drug resistance, and whether inhibition of autophagy using the lysomotrophic agent, chloroquine, can restore chemosensitivity. EXPERIMENTAL METHODS. Inhibition of mTOR was accomplished in human colon cancer cells (HT-29, DLD1) using lentiviral shRNA or by AZD8055, a TORC1 and TORC2 kinase inhibitor. These cells were then incubated with 5-FU (0-100 µM) or CPT-11 (0-20 µM) alone and in combination with chloroquine. LC3I/II expression, phospho-histone H2A.X (a DNA damage marker), and caspase cleavage were analyzed by Western blotting using highly specific antibodies, and clonogenic survival assays were also performed. RESULTS. AZD8055 was shown to attenuate caspase-3 and -9 cleavage and to suppress the expression of phospho-histone H2A.X induced by 5-FU or CPT-11 in colon cancer cells. AZD8055 was also found to antagonize the ability of 5-FU to inhibit clonogenic survival. Similarly, shRNA knockdown of mTOR attenuated 5-FU-induced caspase cleavage and phospho-histone H2A.X expression. Inhibition of mTOR by AZD8055 or shRNA enhanced the conversion of the autophagosome-associated protein light chain 3 (LC3) from a cytosolic (LC3I) to a membrane-bound (LC3II) form, consistent with induction of autophagy. Inhibition of autophagy by chloroquine was shown to attenuate the ability of AZD8055 to suppress 5-FU-induced caspase cleavage. Consistent with this result, chloroquine sensitized DLD1 cells to AZD8055 and 5-FU in a clonogenic survival assay. CONCLUSION. Inhibition of mTOR can protect colon cancer cells from DNA damage induced by cytotoxic chemotherapy. This cytoprotection was due, in part, to induction of pro-survival autophagy since chloroquine was able to partially restore chemosensitivity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5485. doi:10.1158/1538-7445.AM2011-5485
Abstract 5457: Contexts of vulnerability mediating TMZ response in metastatic melanoma
Yin, Holly, Brooks, Bradford, Chow, Donald, Sereduk, Chris , Sekulić, Aleksandar , Trent, Jeff, Brown, Kevin R.

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 5457-5457

10.1158/1538-7445.am2011-5457 Get It

Abstract Metastatic malignant melanoma is an incurable disease with average 5-year survival rates for patients with disseminated disease ranging from 5-18%. Despite the recent development of promising targeted and immunological approaches for treatment of melanoma patients, there remains an urgent need to improve the effectiveness of conventional chemotherapeutics such as TMZ treatment for those patients ineligible or unresponsive to these approaches. We hypothesized that genetic alterations or contexts of vulnerability (COVs) exist in melanoma cells that mediate sensitivity to TMZ, and thus developed RNA-interference-based (RNAi) TMZ chemosensitization assays in melanoma cell lines in order to better understand how to pharmacologically augment TMZ response. First, we extensively developed RNAi sensitization assay in 17 melanoma cell lines followed by screening siRNA kinome library in these cell lines. This screening result, combined with our previous melanoma genomic data (gene expression, aCGH, SNP, and gene mutations), would prioritize the critical essential genes in melanoma. In addition, we profiled 17 melanoma cell lines for TMZ sensitivity and subsequently optimized RNAi screening parameters for detection of TMZ sensitization in one sensitive (UACC903) and four resistant (UACC647, UACC1308, UACC91 and UACC1940) cell lines. We then performed high-throughput RNAi screens with a 7,000 gene siRNA library targeting the druggable genome in these five cell lines. The data from the screens were rigorously evaluated and top TMZ-sensitizing hits were identified and confirmed. Based on these data, we prioritized the ATR/ATM/Chk1 pathway for further evaluation. We tested two Chk1 inhibitors for synergistic effects when combined with TMZ. Notably, both Chk1 inhibitors demonstrated good synergistic effects in the TMZ-resistant cell lines, with moderate/marginal effects in the sensitive line UACC903. These data are consistent with previous reports that inhibition of Chk1 can sensitize TMZ-induced cytotoxicity in glioma cells, and suggest that targeting this pathway in melanoma may augment TMZ response in melanoma. We are presently following up these results across a larger panel of melanoma cell lines, as well as evaluating pharmacological inhibitors of additional TMZ-sensitizing siRNA hits and pathways with the hope that these results may serve as a starting point for the development of novel combination therapies for melanoma patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5457. doi:10.1158/1538-7445.AM2011-5457